TABLE 1.
Characteristics of Subjectsa (n = 64)
| Characteristics | |
|---|---|
| Sex | |
| Males | 38 (59) |
| Females | 26 (41) |
| BMI (kg/m2); mean (SD) | 27.0 (4) |
| <30 | 52 (81) |
| ≥30 | 12 (19) |
| History of hypertension | 45 (70) |
| Current hypertension status (systolic BP/diastolic BP)b | |
| Normal (< 120/80 mm Hg) | 42 (66) |
| Prehypertension (120–139/80–89 mm Hg) | 11 (17) |
| Hypertension (≥ 140/90 mm Hg) | 11 (17) |
| Antihypertensive medicationsc | 55 (86) |
| β-receptor blocking medications | 37 (58) |
| Antiadrenergic agentsd | 6 (9) |
| Calcium channel blockers | 21 (33) |
| Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists | 32 (50) |
| Nonsteroidal anti-inflammatory drugs (person-d)e | 77 (13) |
| 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)c | 41 (64) |
a
Number (%) except where indicated.
b
From ambulatory average.
c
Daily use of each prescription and over-the-counter medication was reported by subjects in paper diaries daily. The subjects counted here took the medication on a regular daily schedule.
d
Includes α2 receptor agonists and α1-adrenergic receptor blocking agents.
e
Includes the total person-days of reported use of aspirin, naproxen, ibuprofen, and celecoxib (% of total person-days of diary reports).
SD indicates standard deviation.